Role of NO/VASP Signaling Pathway Against Obesity-Related Inflammation and Insulin Resistance

Overview

Journal Diabetes Metab J

Specialty Endocrinology

Date 2017 Apr 28

PMID 28447436

Citations 13

Authors

Yu Mi Kang

Francis Kim

Woo Je Lee

Affiliations

Soon will be listed here.

Abstract

Obesity has quickly become a worldwide pandemic, causing major adverse health outcomes such as dyslipidemia, type 2 diabetes mellitus, cardiovascular disease and cancers. Obesity-induced insulin resistance is the key for developing these metabolic disorders, and investigation to understand the molecular mechanisms involved has been vibrant for the past few decades. Of these, low-grade chronic inflammation is suggested as a critical concept in the development of obesity-induced insulin resistance, and the anti-inflammatory effect of nitric oxide (NO) signaling has been reported to be linked to improvement of insulin resistance in multiple organs involved in glucose metabolism. Recently, a body of evidence suggested that vasodilatory-stimulated phosphoprotein (VASP), a downstream mediator of NO signaling plays a crucial role in the anti-inflammatory effect and improvement of peripheral insulin resistance. These preclinical studies suggest that NO/VASP signaling could be an ideal therapeutic target in the treatment of obesity-related metabolic dysfunction. In this review, we introduce studies that investigated the protective role of NO/VASP signaling against obesity-related inflammation and insulin resistance in various tissues.

Citing Articles

VASP Knockdown Ameliorates Lipopolysaccharide-Induced Acute Lung Injury with Inhibition of M1 Macrophage Polarization Through the cGMP-PKG Signaling Pathway.

Tang J, Ding Y, Chen W, Shi J, Zhang C, Zhao X Inflammation. 2025; .

PMID: 40045018 DOI: 10.1007/s10753-025-02277-6.

Urinary and circulatory netrin-1 as biomarker in diabetes and its related complications: a systematic review and meta-analysis.

Behnoush A, Khalaji A, Shokri Varniab Z, Rahbarghazi A, Amini E, Klisic A Endocrine. 2023; 84(2):328-344.

PMID: 37996774 DOI: 10.1007/s12020-023-03598-y.

Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study.

Lee M, Lee J, Sohn S, Lee S, Jeong T, Kim S Diabetol Metab Syndr. 2022; 14(1):56.

PMID: 35449082 PMC: 9022238. DOI: 10.1186/s13098-022-00825-w.

Type 2 Diabetes Complicated With Heart Failure: Research on Therapeutic Mechanism and Potential Drug Development Based on Insulin Signaling Pathway.

Ye H, He Y, Zheng C, Wang F, Yang M, Lin J Front Pharmacol. 2022; 13:816588.

PMID: 35308248 PMC: 8927800. DOI: 10.3389/fphar.2022.816588.

Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model.

Schwartzkopf C, Hadcock J, Liu G, Germano P, Roux J, Shea C Front Pharmacol. 2022; 13:852080.

PMID: 35308230 PMC: 8931041. DOI: 10.3389/fphar.2022.852080.

References

Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M . Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes. 2004; 54(1):166-74. DOI: 10.2337/diabetes.54.1.166. View

Huang P . eNOS, metabolic syndrome and cardiovascular disease. Trends Endocrinol Metab. 2009; 20(6):295-302. PMC: 2731551. DOI: 10.1016/j.tem.2009.03.005. View

Hotamisligil G, Shargill N, Spiegelman B . Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87-91. DOI: 10.1126/science.7678183. View

Tateya S, Rizzo-De Leon N, Handa P, Cheng A, Morgan-Stevenson V, Ogimoto K . VASP increases hepatic fatty acid oxidation by activating AMPK in mice. Diabetes. 2013; 62(6):1913-22. PMC: 3661609. DOI: 10.2337/db12-0325. View

Johlfs M, Fiscus R . Protein kinase G type-Ialpha phosphorylates the apoptosis-regulating protein Bad at serine 155 and protects against apoptosis in N1E-115 cells. Neurochem Int. 2010; 56(4):546-53. DOI: 10.1016/j.neuint.2009.12.017. View

Tateya S, Rizzo N, Handa P, Cheng A, Morgan-Stevenson V, Daum G . Endothelial NO/cGMP/VASP signaling attenuates Kupffer cell activation and hepatic insulin resistance induced by high-fat feeding. Diabetes. 2011; 60(11):2792-801. PMC: 3198085. DOI: 10.2337/db11-0255. View

Arkan M, Hevener A, Greten F, Maeda S, Li Z, Long J . IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med. 2005; 11(2):191-8. DOI: 10.1038/nm1185. View

Handa P, Tateya S, Rizzo N, Cheng A, Morgan-Stevenson V, Han C . Reduced vascular nitric oxide-cGMP signaling contributes to adipose tissue inflammation during high-fat feeding. Arterioscler Thromb Vasc Biol. 2011; 31(12):2827-35. PMC: 3342311. DOI: 10.1161/ATVBAHA.111.236554. View

Wong J, Fiscus R . Essential roles of the nitric oxide (no)/cGMP/protein kinase G type-Iα (PKG-Iα) signaling pathway and the atrial natriuretic peptide (ANP)/cGMP/PKG-Iα autocrine loop in promoting proliferation and cell survival of OP9 bone marrow stromal cells. J Cell Biochem. 2011; 112(3):829-39. DOI: 10.1002/jcb.22981. View

10.

Cheng A, Rizzo-DeLeon N, Wilson C, Lee W, Tateya S, Clowes A . Vasodilator-stimulated phosphoprotein protects against vascular inflammation and insulin resistance. Am J Physiol Endocrinol Metab. 2014; 307(7):E571-9. PMC: 4187027. DOI: 10.1152/ajpendo.00303.2014. View

11.

Rizzo N, Maloney E, Pham M, Luttrell I, Wessells H, Tateya S . Reduced NO-cGMP signaling contributes to vascular inflammation and insulin resistance induced by high-fat feeding. Arterioscler Thromb Vasc Biol. 2010; 30(4):758-65. PMC: 2865555. DOI: 10.1161/ATVBAHA.109.199893. View

12.

Gruber H, Mayer C, Mangge H, Fauler G, Grandits N, Wilders-Truschnig M . Obesity reduces the bioavailability of nitric oxide in juveniles. Int J Obes (Lond). 2008; 32(5):826-31. DOI: 10.1038/sj.ijo.0803795. View

13.

Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Chayama K, Oshima T . Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens. 2001; 14(10):1038-45. DOI: 10.1016/s0895-7061(01)02191-4. View

14.

Westerbacka J, Corner A, Kolak M, Makkonen J, Turpeinen U, Hamsten A . Insulin regulation of MCP-1 in human adipose tissue of obese and lean women. Am J Physiol Endocrinol Metab. 2008; 294(5):E841-5. DOI: 10.1152/ajpendo.00653.2006. View

15.

Yan C, Kim D, Aizawa T, Berk B . Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscler Thromb Vasc Biol. 2003; 23(1):26-36. DOI: 10.1161/01.atv.0000046231.17365.9d. View

16.

Liu V, Huang P . Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res. 2007; 77(1):19-29. PMC: 2731989. DOI: 10.1016/j.cardiores.2007.06.024. View

17.

Leung E, Wong J, Johlfs M, Tsang B, Fiscus R . Protein kinase G type Ialpha activity in human ovarian cancer cells significantly contributes to enhanced Src activation and DNA synthesis/cell proliferation. Mol Cancer Res. 2010; 8(4):578-91. DOI: 10.1158/1541-7786.MCR-09-0178. View

18.

Xu H, Barnes G, Yang Q, Tan G, Yang D, Chou C . Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112(12):1821-30. PMC: 296998. DOI: 10.1172/JCI19451. View

19.

Braet F, Wisse E . Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002; 1(1):1. PMC: 131011. DOI: 10.1186/1476-5926-1-1. View

20.

Lundberg J, Carlstrom M, Larsen F, Weitzberg E . Roles of dietary inorganic nitrate in cardiovascular health and disease. Cardiovasc Res. 2010; 89(3):525-32. DOI: 10.1093/cvr/cvq325. View